Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer

Although several clinical trials have suggested that postoperative adjuvant chemotherapy can improve survival of patients with gastric cancer, the optimal treatment duration has not been studied. This retrospective analysis evaluated the outcomes of patients with gastric cancer treated with six cycl...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013, Vol.8 (12), p.e83196
Main Authors: Qu, Jing-lei, Li, Xin, Qu, Xiu-Juan, Zhu, Zhi-tu, Zhou, Li-zhong, Teng, Yue-e, Zhang, Jing-dong, Jin, Bo, Zhao, Ming-fang, Yu, Ping, Liu, Yun-peng
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adult
Aged
Breast cancer
Cancer
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant - adverse effects
Chemotherapy, Adjuvant - methods
Clinical trials
Cohort Studies
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Fluorouracil - therapeutic use
Gastrectomy
Gastric cancer
Humans
Lung cancer
Lymphatic system
Male
Medical research
Middle Aged
Mortality
Multivariate analysis
Oncology
Oxaliplatin
Patients
Retrospective Studies
Statistical analysis
Stomach cancer
Stomach Neoplasms - drug therapy
Stomach Neoplasms - surgery
Subgroups
Surgery
Survival
Survival Analysis
Time Factors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although several clinical trials have suggested that postoperative adjuvant chemotherapy can improve survival of patients with gastric cancer, the optimal treatment duration has not been studied. This retrospective analysis evaluated the outcomes of patients with gastric cancer treated with six cycles of fluorouracil-based treatment compared with a cohort treated with four or eight cycles. We retrospectively identified 237 patients with stage IB-IIIC gastric cancer who received four, six, or eight cycles of fluorouracil-based adjuvant chemotherapy administered every 3 weeks after radical gastrectomy. The endpoint was overall survival (OS). Factors associated with prognosis were also analyzed. The estimated 3-year OS rates for the four-, six-, and eight-cycle cohorts were 54.4%, 76.1%, and 68.9%, respectively; and the estimated 5-year OS rates were 41.2%, 74.0%, and 65.8%, respectively. Patients who received six cycles were more likely to have a better OS than those who received four cycles (P = 0.002). Eight cycles failed to show an additional survival benefit (P = 0.454). In the multivariate analysis, the number of chemotherapy cycles was associated with OS independent of clinical covariates (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0083196